Skip to main content
. 2020 Dec 15;17(4):1014–1025. doi: 10.20892/j.issn.2095-3941.2020.0157

Table 1.

Relationship between different drug-resistant genes and clinicopathological variables of breast cancers

Total Topo II
P LRP
P GST-π
P P-gp
P
− (%) + (%) − (%) + (%) − (%) + (%) − (%) + (%)
Histological grade 0.001* 0.78 0.45 0.08
I 16 14 (87.5) 2 (12.5) 8 (50.0) 8 (50.0) 6 (37.5) 10 (62.5) 8 (50.0) 8 (50.0)
II 336 150 (44.6) 186 (55.4) 176 (52.3) 160 (47.6) 162 (48.2) 174 (51.8) 149 (44.3) 187 (55.7)
III 196 81 (41.3) 115 (58.7) 90 (45.9) 106 (54.1) 86 (43.9) 110 (56.1) 68 (34.7) 128 (65.3)
Vessel thrombus 0.89 0.17 0.47 0.43
Negative 500 211 (42.2) 289 (57.8) 246 (49.2) 244 (48.8) 242 (48.4) 258 (51.6) 202 (40.4%) 298 (59.6%)
Positive 48 34 (70.8) 14 (29.2) 28 (58.3) 20 (42.7) 22 (45.8) 26 (54.2) 23 (47.9%) 25 (52.1%)
Clinical stage 0.73 0.14 0.62 0.90
I 37 15 (40.5) 22 (59.5) 14 (37.8) 23 (62.2) 11 (29.7) 26 (60.3) 16 (43.2) 21 (56.8)
II 359 157 (43.7) 202 (56.3) 180 (50.1) 179 (49.9) 162 (45.1) 197 (54.9) 143 (39.8) 216 (60.2)
III 152 73 (48.0) 79 (52.0) 80 (52.6) 72 (47.4) 81 (53.3) 71 (46.7) 66 (43.4) 86 (56.6)
Lymph node metastasis 0.73 0.99 0.55 0.80
Negative 230 104 (45.2) 126 (54.8) 114 (49.6) 116 (50.4) 101 (43.9) 129 (56.1) 91 (39.6) 139 (60.4)
Positive 318 141 (44.3) 177 (55.7) 160 (50.3) 158 (49.7) 153 (48.1) 165 (51.9) 134 (42.1) 184 (57.9)
Age (mean ± SD) 0.5 0.15 0.66 0.33
52.9±6.7 52.1±5.8 51.2±7.9 53.9±5.8 52.7±6.7 52.2±5.9 51.8±8.6 52.9±6.2
Tumor size (mean ± SD) 0.49 0.28 0.17 0.84
3.0±2.5 3.0±2.7 3.1±2.7 2.9±2.3 3.1±3.0 2.9±2.6 3.0±2.7 2.9±2.8
a

The Fisher test was used when N < 5; *P < 0.05.